Published in Nat Rev Cardiol on June 02, 2009
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (2010) 4.67
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol (2010) 2.23
HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A (2011) 2.16
Uremia alters HDL composition and function. J Am Soc Nephrol (2011) 1.55
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest (2011) 1.46
Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep (2010) 1.46
An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med (2014) 1.33
High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol (2012) 1.16
Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res (2012) 1.13
Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med (2015) 1.07
4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J (2010) 0.99
Influence of C-terminal α-helix hydrophobicity and aromatic amino acid content on apolipoprotein A-I functionality. Biochim Biophys Acta (2011) 0.96
Folded functional lipid-poor apolipoprotein A-I obtained by heating of high-density lipoproteins: relevance to high-density lipoprotein biogenesis. Biochem J (2012) 0.94
The protein cargo of HDL: implications for vascular wall biology and therapeutics. J Clin Lipidol (2010) 0.94
Regulation of ABCA1 functions by signaling pathways. Biochim Biophys Acta (2011) 0.90
PON-dering differences in HDL function in coronary artery disease. J Clin Invest (2011) 0.90
Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol (2012) 0.89
Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ Res (2013) 0.88
Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One (2014) 0.88
Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retroviruses (2014) 0.87
HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Des (2010) 0.87
Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J Lipid Res (2011) 0.86
Nanotechnology for synthetic high-density lipoproteins. Trends Mol Med (2010) 0.86
HDL--is it too big to fail? Nat Rev Endocrinol (2013) 0.86
How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep (2013) 0.84
MicroRNAs involved in the lipid metabolism and their possible implications for atherosclerosis development and treatment. Mediators Inflamm (2014) 0.84
ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis. J Lipid Res (2011) 0.84
Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice. J Lipid Res (2015) 0.84
Serum lipids, apolipoproteins, and mortality among coronary artery disease patients. Biomed Res Int (2014) 0.83
A novel fluorogenic substrate for the measurement of endothelial lipase activity. J Lipid Res (2011) 0.83
Probucol alleviates atherosclerosis and improves high density lipoprotein function. Lipids Health Dis (2011) 0.83
Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice. J Lipid Res (2014) 0.83
Effect of bariatric surgery on microvascular dysfunction associated to metabolic syndrome: a 12-month prospective study. Int J Obes (Lond) (2014) 0.82
Atomistic MD simulation reveals the mechanism by which CETP penetrates into HDL enabling lipid transfer from HDL to CETP. J Lipid Res (2014) 0.81
Human apoA-I increases macrophage foam cell derived PLTP activity without affecting the PLTP mass. Lipids Health Dis (2010) 0.81
Effect of hyperlipidemia on femoral biomechanics and morphology in low-density lipoprotein receptor gene knockout mice. J Bone Miner Metab (2012) 0.78
The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice. Lipids Health Dis (2013) 0.78
ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. J Lipid Res (2012) 0.78
Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein. Cardiol Res Pract (2012) 0.78
CETP expression reverses the reconstituted HDL-induced increase in VLDL. J Lipid Res (2011) 0.78
Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages. J Biol Chem (2016) 0.77
P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo. PLoS One (2014) 0.77
Utilizing imaging tools in lipidology: examining the potential of MRI for monitoring cholesterol therapy. Clin Lipidol (2012) 0.77
Preparation and activity analysis of recombinant human high-density lipoprotein. Assay Drug Dev Technol (2012) 0.75
Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism. J Biol Chem (2015) 0.75
The Impact of Lipoproteins on Wound Healing: Topical HDL Therapy Corrects Delayed Wound Healing in Apolipoprotein E Deficient Mice. Pharmaceuticals (Basel) (2014) 0.75
Lipid Abnormalities and Inflammation in HIV Inflection. Curr HIV/AIDS Rep (2016) 0.75
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 6.52
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation (2000) 4.87
ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab (2005) 4.79
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest (2007) 4.20
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A (2004) 4.05
Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest (2006) 3.76
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation (2006) 3.49
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2005) 3.25
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A (1994) 3.24
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 3.24
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med (1990) 3.02
The macrophage foam cell as a target for therapeutic intervention. Nat Med (2002) 2.98
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation (1999) 2.84
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol (2004) 2.64
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62
A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet (1999) 2.56
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett (2003) 2.52
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest (2005) 2.47
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med (2005) 2.40
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest (2006) 2.36
Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation (1999) 2.27
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J (2008) 2.26
High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol (2000) 2.21
Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature (2003) 2.14
Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun (2003) 2.00
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol (2008) 1.97
Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature (1989) 1.91
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation (2002) 1.89
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest (2005) 1.88
beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest (2009) 1.79
Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation (2002) 1.72
Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest (2003) 1.72
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res (2004) 1.70
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65
ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest (2001) 1.61
A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol (2007) 1.53
Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med (2005) 1.52
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther (2007) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res (2004) 1.31
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol (2005) 1.30
Endothelial lipase is increased in vivo by inflammation in humans. Circulation (2008) 1.27
Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A (1996) 1.27
Compromised LCAT function is associated with increased atherosclerosis. Circulation (2005) 1.23
Synthetic LXR agonists increase LDL in CETP species. J Lipid Res (2005) 1.22
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol (2007) 1.22
Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem (1999) 1.21
Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res (2001) 1.20
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA (2007) 1.14
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res (2009) 1.08
Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun (2005) 1.06
Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. J Lipid Res (2007) 1.05
ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest (1999) 1.03
N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J Med Chem (2007) 1.01
Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol (1999) 1.00
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res (2008) 0.98
Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol (2000) 0.94
Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol (1996) 0.94
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 0.92
Apolipoprotein A-I(Milano): current perspectives. Curr Opin Lipidol (2003) 0.92
Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett (2008) 0.87
Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler Thromb Vasc Biol (2008) 0.83
Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther (2006) 0.81
High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA (2003) 0.81
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med (2003) 9.23
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med (2009) 4.45
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 4.37
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest (2007) 4.20
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med (2007) 3.70
Resistin is an inflammatory marker of atherosclerosis in humans. Circulation (2005) 3.52
Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol (2002) 3.51
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation (2006) 3.49
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med (2004) 3.34
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2005) 3.25
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 3.24
The metabolic syndrome: more than the sum of its parts? Circulation (2003) 3.22
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol (2010) 3.20
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med (2003) 2.98
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res (2005) 2.61
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med (2004) 2.51
CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med (2014) 2.50
Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest (2005) 2.47
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol (2008) 2.41
The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res (2007) 2.38
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 2.37
Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA (2003) 2.32
Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis (2011) 2.25
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Characterization of the lipolytic activity of endothelial lipase. J Lipid Res (2002) 2.16
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Statins and cognitive function: a systematic review. Ann Intern Med (2013) 2.10
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med (2008) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Illuminating HDL--is it still a viable therapeutic target? N Engl J Med (2007) 1.94
Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation (2007) 1.93
Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol (2011) 1.91
CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol (2007) 1.87
Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.85
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest (2009) 1.83
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res (2005) 1.77
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.76
Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation (2002) 1.72
Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest (2003) 1.72
Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest (2012) 1.71
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med (2012) 1.71
Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol (2007) 1.70
Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification. Arterioscler Thromb Vasc Biol (2010) 1.69
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol (2009) 1.68
Hepatic proprotein convertases modulate HDL metabolism. Cell Metab (2007) 1.68
Laboratory assessment of HDL heterogeneity and function. Clin Chem (2008) 1.67
Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res (2005) 1.66
Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A (2003) 1.65
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet (2011) 1.63
Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation (2004) 1.62
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res (2010) 1.60
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.58
Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab (2004) 1.55
A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med (2004) 1.53
Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med (2005) 1.52